These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 16339703

  • 1. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 2. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 3. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 4. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S, Tang H, Jensen JH, Altmann K, Prakash A, Printz BF, Hordof AJ, Tosti CL, Azabagic A, Swaminathan S, Brown TR, Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
    [Abstract] [Full Text] [Related]

  • 5. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 6. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 8. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Apr; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 9. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
    Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M.
    Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
    [Abstract] [Full Text] [Related]

  • 10. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 11. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.
    Hemoglobin; 2014 Aug 15; 38(2):111-4. PubMed ID: 24351163
    [Abstract] [Full Text] [Related]

  • 12. Measurement and mapping of liver iron concentrations using magnetic resonance imaging.
    St Pierre TG, Clark PR, Chua-Anusorn W.
    Ann N Y Acad Sci; 2005 Aug 15; 1054():379-85. PubMed ID: 16339686
    [Abstract] [Full Text] [Related]

  • 13. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, Engelhardt R, Dürken M, Nielsen P.
    Ann N Y Acad Sci; 2005 Aug 15; 1054():429-32. PubMed ID: 16339692
    [Abstract] [Full Text] [Related]

  • 14. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
    Ha SY, Mok AS, Chu WC, Rasalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2011 Aug 15; 35(3):199-205. PubMed ID: 21599432
    [Abstract] [Full Text] [Related]

  • 15. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug 15; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW.
    N Engl J Med; 1994 Sep 01; 331(9):567-73. PubMed ID: 8047080
    [Abstract] [Full Text] [Related]

  • 17. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct 01; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 18. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul 01; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 19. Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.
    Drakonaki EE, Maris TG, Maragaki S, Klironomos V, Papadakis A, Karantanas AH.
    Hemoglobin; 2010 Jul 01; 34(1):95-106. PubMed ID: 20113293
    [Abstract] [Full Text] [Related]

  • 20. Barriers to adherence of deferoxamine usage in sickle cell disease.
    Treadwell MJ, Law AW, Sung J, Hackney-Stephens E, Quirolo K, Murray E, Glendenning GA, Vichinsky E.
    Pediatr Blood Cancer; 2005 May 01; 44(5):500-7. PubMed ID: 15602707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.